BioDelivery Sciences International, Inc. (NASDAQ:BDSI) Director Mark A. Sirgo sold 162,509 shares of the company’s stock in a transaction on Wednesday, January 3rd. The stock was sold at an average price of $2.78, for a total value of $451,775.02. Following the transaction, the director now directly owns 1,759,262 shares in the company, valued at approximately $4,890,748.36. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
BioDelivery Sciences International, Inc. (NASDAQ:BDSI) traded up $0.12 during trading on Friday, reaching $2.70. The company’s stock had a trading volume of 532,970 shares, compared to its average volume of 599,860. The company has a debt-to-equity ratio of 1.89, a current ratio of 1.28 and a quick ratio of 1.07. The firm has a market capitalization of $150.89, a price-to-earnings ratio of 30.00 and a beta of 0.74. BioDelivery Sciences International, Inc. has a 12 month low of $1.55 and a 12 month high of $3.60.
BioDelivery Sciences International (NASDAQ:BDSI) last posted its earnings results on Thursday, November 9th. The specialty pharmaceutical company reported ($0.21) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.22) by $0.01. The company had revenue of $11.25 million for the quarter, compared to analyst estimates of $9.40 million. BioDelivery Sciences International had a return on equity of 33.83% and a net margin of 10.40%. BioDelivery Sciences International’s revenue was up 215.1% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.30) earnings per share. equities research analysts anticipate that BioDelivery Sciences International, Inc. will post 0.16 earnings per share for the current fiscal year.
A number of institutional investors have recently bought and sold shares of BDSI. Wells Fargo & Company MN grew its holdings in BioDelivery Sciences International by 138.2% in the third quarter. Wells Fargo & Company MN now owns 35,506 shares of the specialty pharmaceutical company’s stock valued at $105,000 after purchasing an additional 20,599 shares during the last quarter. JPMorgan Chase & Co. acquired a new stake in BioDelivery Sciences International in the third quarter valued at $116,000. Advisor Group Inc. grew its holdings in BioDelivery Sciences International by 42.1% in the second quarter. Advisor Group Inc. now owns 45,066 shares of the specialty pharmaceutical company’s stock valued at $126,000 after purchasing an additional 13,341 shares during the last quarter. Northern Trust Corp grew its holdings in BioDelivery Sciences International by 0.9% in the second quarter. Northern Trust Corp now owns 140,450 shares of the specialty pharmaceutical company’s stock valued at $394,000 after purchasing an additional 1,203 shares during the last quarter. Finally, Krilogy Financial LLC grew its holdings in BioDelivery Sciences International by 28.8% in the third quarter. Krilogy Financial LLC now owns 134,000 shares of the specialty pharmaceutical company’s stock valued at $395,000 after purchasing an additional 30,000 shares during the last quarter. 44.08% of the stock is currently owned by institutional investors.
COPYRIGHT VIOLATION NOTICE: “BioDelivery Sciences International, Inc. (BDSI) Director Mark A. Sirgo Sells 162,509 Shares” was posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright and trademark legislation. The legal version of this story can be read at https://www.chaffeybreeze.com/2018/01/19/biodelivery-sciences-international-inc-bdsi-director-mark-a-sirgo-sells-162509-shares.html.
BioDelivery Sciences International Company Profile
BioDelivery Sciences International, Inc is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction.
Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.